Vanderbilt Center for Antibody Therapeutics (VCAT)

Clinical investigation society lauds impact of Crowe’s research

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017 recipient of the Stanley J. Korsmeyer Award given by the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected honor societies for physician-scientists.

Crowe’s pediatric immune response research lauded

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

Digestive Disease Research Center lands major grant

The Vanderbilt Digestive Disease Research Center (VDDRC) celebrates its 15th anniversary this year with a third consecutive five-year renewal of its federal research grant.

Early study finds antibody that ‘neutralizes’ Zika virus

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

Preparing for a return of pox

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.

1 7 8 9 10 11 14